Ovarian Cancer (OvCa)
Conditions
Brief summary
The goal of this observational study is to determine the urinary proteomic characteristics in women with and without ovarian cancer. The main questions it aims to answer are: 1. What is the difference in urinary protein composition between patients with ovarian cancer and those without it? 2. Can these differences in urinary protein composition aid in the diagnosis of ovarian cancer? 3. Are urinary protein markers associated with tumor burden in urine samples from patients with ovarian cancer? 4. Can urinary protein markers be used for disease surveillance in ovarian cancer patients?
Interventions
None listed
Sponsors
Xiangya Hospital of Central South University
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Female patients in the gynecological ward for surgical treatment. * Initial diagnosis of pelvic mass or malignant ascites may be considered as ovarian cancer; Or the initial diagnosis of ovarian cyst, hydrosalpinx, uterine fibroids or uterine adenomyosis are considered as gynecological non-malignant diseases. * Over 18 years of age. * Voluntary participation and signing of informed consent.
Exclusion criteria
* Study participants with a prior history of malignant tumors. * Study participants with prior chronic kidney disease or renal insufficiency. * Study participants who have received or are receiving treatment for primary disease. * Study participants whose pathological diagnosis was not clear. Any patient should be excluded from the study if: * Study participants withdraw informed consent and request withdrawal. * Study participants were unable to provide a qualified urine sample. * There are situations in which the researcher considers it necessary to withdraw from the study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Pathological diagnosis | From enrollment to the end of surgery or biopsy at 1 weeks | The histological type of the disease is confirmed by surgery or biopsy |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Progression | From enrollment to the end of treatment at 6 months | Patients with ovarian cancer who have recurrent disease after initial treatment with serological or imaging evidence |
Countries
China
Contacts
Primary ContactYu Zhang, PhD
Outcome results
None listed